Article

Estimating the population-level kidney benefits of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease in Australian primary care

2023-06-28

Abstract excerpt

<h4>Background</h4> Although sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of kidney failure and death in patients with chronic kidney disease (CKD), they are underused in routine clinical practice. We evaluated the number of patients with CKD in Australia that would be eligible for treatment with an SGLT2 inhibitor and estimated the number of cardiorenal and kidney failure events that could b...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 935bb452-e5b2-5b1a-a467-1f861b18c8fe
DOI: 10.1101/2023.06.26.23291881

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Estimating the population-level kidney benefits of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease in Australian primary careDOI 10.1101/2023.06.26.23291881Read

The prevalence of chronic kidney disease in Australian primary care: analysis of a national general practice datasetSemantic proximity Read

Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in the Very Elderly with Chronic Kidney Disease: a Retrospective Cohort Study Using Real-World DataSemantic proximity Read

Cardiorenal outcomes of tirzepatide versus semaglutide in adults with type 2 diabetes and chronic kidney disease: a target trial emulation in the TriNetX Global Collaborative NetworkSemantic proximity Read

Projected impact on blood pressure, chronic kidney disease burden and healthcare costs of achieving the Australian sodium reduction targets: a modelling studySemantic proximity Read

Inference of Disease Burden for Chronic Kidney Disease Screening Intervention Based on a Micro-Simulation ModelSemantic proximity Read

Quality Use Of Medicines In Patients With Chronic Kidney DiseaseSemantic proximity Read

Chronic Kidney Disease.Semantic proximity Read

Cardiometabolic drugs and kidney function – a drug target Mendelian randomisation studySemantic proximity Read

Effect of SGLT2 Inhibitors on CKD Progression and All-Cause Mortality: A Meta-Analysis of Randomized Controlled TrialsSemantic proximity Read

Tackling the Inverse Care Law with pharmacist-led cardio-renal-metabolic service in a socioeconomically deprived population: A prospective scoping intervention studySemantic proximity Read

Predicting and Validating Risk of Pre-Pandemic and Excess Mortality in Individuals With Chronic Kidney DiseaseSemantic proximity Read

Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy.Semantic proximity Read